Stemtech Corporation Receives Strategic Funding From Leading Company in Direct-to-Consumer Sector - Seite 2

About Sharing Services Global Corporation

Sharing Services Global Corporation (OTCQB: SHRG), formerly Sharing Services Inc., is a publicly traded diversified company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. One of its primary divisions is Elevacity U.S., LLC a sales and marketing company based on utilization of independent contractors as the sales force). For more information, visit: www.SHRGInc.com.

About RHK Noble Capital Markets

RHK Noble Capital Markets does business through Noble Capital Markets, Inc. a research-driven investment bank and broker dealer focused on small cap emerging growth companies in the healthcare, technology, media, transportation & logistics and natural resources sectors. Its people are talented, dedicated, experienced professionals who come together with a common cause; advising on long-term client-solutions by employing innovative, collaborative and responsive strategies. They are passionate and personable approaching things from their clients' perspective. Empowering their clients to create employment, engineer technological and medical breakthroughs, producing products and services that lay the foundation for the future. For more than 30 years these have been Noble’s guiding principles. Noble is registered with FINRA, SIPC and MSRB. For more information please visit: Investment Banking - Noble Capital Markets.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q filed July 13^th, 2021. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.